AB1178 An audit of originator adalimumab to biosimilar switch in two hospitals

Mazumder, R., Loke, M., Mukhtyar, C. ORCID: https://orcid.org/0000-0002-9771-6667, Gaffney, K. ORCID: https://orcid.org/0000-0002-7863-9176, Balogh, E., Sekaran, E., Sultana, M., Odonkor, M. and Miles, K. (2020) AB1178 An audit of originator adalimumab to biosimilar switch in two hospitals. Annals of the Rheumatic Diseases, 79 (Suppl 1). ISSN 0003-4967

Full text not available from this repository.


Background: Biological drugs have revolutionized the treatment of immune-mediated inflammatory diseases (IMIDs). Current guidelines reserve these drugs for patients with severe refractory disease. Biologic drugs are expensive, but as they reach patent expiry, the introduction of lower-cost biosimilars reduces their impact on health care budgets. It is estimated that NHS England could save £300 million by 2021 following the recent launch of adalimumab biosimilars [1]. As part of this process, there has been a mandatory switch of originator adalimumab to biosimilar adalimumab throughout the U.K. Objectives: To evaluate the impact of the switch to biosimilar adalimumab in individuals with inflammatory arthritis at two NHS trusts in the East of England and calculate the proportion and reasons for switch back to originator adalimumab or a second biosimilar at 12 weeks. Methods: Both hospitals ran dedicated ‘switch’ clinics. All patient records were reviewed retrospectively. Results: 855 patients with different IMID switched from originator to biosimilar over 13 months. At 12 weeks, 730 patients (85%) maintained the switch, 71 patients (8.7%) switched back to the originator, and 54 patients (6.3%) switched to other biosimilars of the same drug.

Item Type: Article
Depositing User: LivePure Connector
Date Deposited: 11 Apr 2022 09:30
Last Modified: 25 Aug 2022 15:45
URI: https://ueaeprints.uea.ac.uk/id/eprint/84561
DOI: 10.1136/annrheumdis-2020-eular.4709

Actions (login required)

View Item View Item